

mondobIOTECH holding AG (SIX:RARE): Presenting at the Biotech in Europe Investor Forum in Zurich

Stans, 23 September 2010 – mondobIOTECH's Chief Scientific Officer and co-founder Dr. Dorian Bevec will present the company at the upcoming 10th Annual Biotech in Europe Investor Forum on Wednesday, September 29th, 2010 at 3:15 p.m. at the Zurich Airport Radisson Blu Hotel, Room Lucerne, Level 7.

This September the mondobIOTECH Rare Diseases Pipeline was granted its 7th Orphan Drug Designation from the United States FDA for the treatment of Berylliosis, further rewarding mondobIOTECH continuous mission to find treatments for rare diseases.

About Mondobiotech

mondobIOTECH (SIX Swiss Exchange ticker symbol: RARE), an independent Swiss biotech company, discovers drugs for patients suffering from rare diseases through its proprietary Search & Match methodology. In Search & Match mondobIOTECH's scientists combine their unique knowledge of biologically active human peptides with advanced technology solutions delivering remedies for rare diseases to licensing partners.

For further information please contact:

mondobIOTECH holding AG
Investor Relations, Mr. Paolo Bassanini
Das Kloster
Mürgstrasse 18
CH-6370 Stans
Tel.: +41 (0) 840 200 010
Fax: +41 (0) 840 200 011
investor@mondobiotech.com
www.mondobiotech.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning mondobIOTECH holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of mondobIOTECH holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. mondobIOTECH holding AG is providing

this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.